FOX CHASE CANCER CENTER

๐Ÿ‡บ๐Ÿ‡ธUnited States
Ownership
-
Established
1904-01-01
Employees
-
Market Cap
-
Website
http://www.foxchase.org

Celecoxib in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia

First Posted Date
2005-01-10
Last Posted Date
2013-07-11
Lead Sponsor
Fox Chase Cancer Center
Registration Number
NCT00101335
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Cisplatin, Interferon Alfa, Surgery, and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma

Phase 1
Completed
Conditions
First Posted Date
2004-09-13
Last Posted Date
2013-04-17
Lead Sponsor
Fox Chase Cancer Center
Target Recruit Count
6
Registration Number
NCT00003263
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

๐Ÿ‡บ๐Ÿ‡ธ

Office of S. Terry Kraus, Marrero, Louisiana, United States

๐Ÿ‡บ๐Ÿ‡ธ

Virginia Oncology Associates, Newport News, Virginia, United States

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

Phase 2
Completed
Conditions
First Posted Date
2004-08-05
Last Posted Date
2013-04-17
Lead Sponsor
Fox Chase Cancer Center
Target Recruit Count
3
Registration Number
NCT00003957
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Genetic and Environmental Risk Assessment for Colorectal Cancer in Healthy Participants

Not Applicable
Completed
Conditions
First Posted Date
2004-07-12
Last Posted Date
2013-07-11
Lead Sponsor
Fox Chase Cancer Center
Registration Number
NCT00087360
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

๐Ÿ‡บ๐Ÿ‡ธ

Kimmel Cancer Center at Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States

๐Ÿ‡บ๐Ÿ‡ธ

Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States

and more 1 locations

Irinotecan Plus Raltitrexed in Treating Patients With Refractory Solid Tumors

First Posted Date
2004-07-08
Last Posted Date
2013-04-17
Lead Sponsor
Fox Chase Cancer Center
Target Recruit Count
39
Registration Number
NCT00003109
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer

Phase 2
Withdrawn
Conditions
First Posted Date
2004-06-11
Last Posted Date
2013-07-10
Lead Sponsor
Fox Chase Cancer Center
Registration Number
NCT00084565

Intensity-Modulated Radiation Therapy With or Without Decreased Radiation Dose to Erectile Tissue in Treating Patients With Stage II Prostate Cancer

First Posted Date
2004-06-11
Last Posted Date
2021-02-25
Lead Sponsor
Fox Chase Cancer Center
Target Recruit Count
116
Registration Number
NCT00084552
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States

Trastuzumab and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic HER2/Neu-Expressing Cancer

First Posted Date
2004-06-11
Last Posted Date
2010-02-12
Lead Sponsor
Fox Chase Cancer Center
Target Recruit Count
18
Registration Number
NCT00084513
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Computed Tomography (CT) Scans Using CT-On-Railsโ„ข to Pinpoint the Location of the Tumor in Treating Patients With Prostate Cancer

Phase 1
Completed
Conditions
First Posted Date
2004-06-11
Last Posted Date
2010-02-12
Lead Sponsor
Fox Chase Cancer Center
Target Recruit Count
40
Registration Number
NCT00084526
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States

ยฉ Copyright 2024. All Rights Reserved by MedPath